Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BIO-TECHNE (TECH) EBIT: 2009-2025

Historic EBIT for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to $47.7 million.

  • BIO-TECHNE's EBIT rose 19.18% to $47.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.9 million, marking a year-over-year decrease of 42.39%. This contributed to the annual value of $102.3 million for FY2025, which is 50.53% down from last year.
  • Latest data reveals that BIO-TECHNE reported EBIT of $47.7 million as of Q3 2025, which was up 299.74% from -$23.9 million recorded in Q2 2025.
  • Over the past 5 years, BIO-TECHNE's EBIT peaked at $94.5 million during Q2 2023, and registered a low of -$23.9 million during Q2 2025.
  • For the 3-year period, BIO-TECHNE's EBIT averaged around $48.3 million, with its median value being $47.4 million (2024).
  • Its EBIT has fluctuated over the past 5 years, first surged by 74.46% in 2021, then slumped by 152.07% in 2025.
  • Over the past 5 years, BIO-TECHNE's EBIT (Quarterly) stood at $62.3 million in 2021, then grew by 8.89% to $67.9 million in 2022, then tumbled by 44.02% to $38.0 million in 2023, then climbed by 24.77% to $47.4 million in 2024, then grew by 19.18% to $47.7 million in 2025.
  • Its EBIT stands at $47.7 million for Q3 2025, versus -$23.9 million for Q2 2025 and $38.7 million for Q1 2025.